Table I.
Inhibitory effects of curcumin and its analogues on the growth of CWR-22Rv1 cells.
| Compound | IC50, µM | P-value |
|---|---|---|
| Curcumin | 16.99±2.1 | 0.00092 |
| AN1 | 0.53±0.1 | 0.00065 |
| AN2 | 0.92±0.1 | 0.00071 |
| AN3 | 0.95±0.2 | 0.00065 |
| BN1 | 4.75±0.5 | 0.00095 |
| BN2 | 4.99±0.5 | 0.00096 |
| BN3 | 3.03±0.4 | 0.00083 |
| EN1 | 2.18±0.2 | 0.00079 |
| EN2 | 1.07±0.1 | 0.00080 |
| EN3 | 1.80±0.2 | 0.00082 |
| FN1 | 0.66±0.1 | 0.00072 |
| FN2 | 0.55±0.1 | 0.00073 |
| FN3 | 0.49±0.1 | 0.00061 |
CWR-22Rv1 prostate cancer cells were seeded at a density of 2×104 cells/ml of medium in 96-well plates (0.2 ml/well) and incubated for 24 h. The cells were then treated with various concentrations (0.5–30 µM) of curcumin and its analogues for 72 h. Effects of the different compounds on the growth of CWR-22Rv1 cells were determined by performing a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. Values are presented as the mean ± standard error of the mean from three separate experiments. IC50, half maximal inhibitory concentration; AN1/2/3, (2E,6E)-2,6-bis(pyridin-2/3/4-methylene)cyclohexanone; BN1/2/3, (2E,5E)-2,5-bis(pyridin-2/3/4-methylene)cyclopentanone; EN1/2/3, (3E,5E)-3,5-bis(pyridin-2/3/4-methylene)-tetrahydropyran-4-one; FN1/2/3, (3E,5E)-3,5-bis(pyridin-2/3/4-methylene)-tetrahydrothiopyran-4-one.